Vijaya Diagnostic Centre
- P/E
- 78.15
Key Fundamentals
SmallcapHealthcare ServicesHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 20.50%
- Debt to Equity
- 0.44
- EPS (TTM)
- ₹18.23
- Book Value
- ₹92.93
- Market Cap
- —
- P/E (TTM)
- 78.15
- P/B
- 15.33
- ROE
- 18.30%
- Dividend Yield
- 0.14%
- EBITDA
- ₹358 Cr
- 52W High
- ₹1,593.60
- 52W Low
- ₹848.00
- Volume
- 0
Peer Comparison
Healthcare › Healthcare Services › Healthcare Service Provider
| ₹2,029.40 | 62.75 | ₹32,036 Cr | 13.58 | 0.26% | 22.30% | 28.00% | ₹2,891 Cr | ₹545 Cr | |
| Vijaya Diagnostic Centre (this company) | ₹1,424.60 | 78.15 | ₹14,588 Cr | 15.33 | 0.14% | 18.30% | 20.50% | ₹857 Cr | ₹187 Cr |
| ₹581.25 | 59.74 | ₹11,437 Cr | 8.03 | 0.88% | 13.60% | 17.80% | ₹1,710 Cr | ₹203 Cr | |
| ₹495.50 | 44.72 | ₹7,723 Cr | 14.25 | 2.90% | 28.40% | 35.40% | ₹876 Cr | ₹176 Cr | |
| ₹622.35 | 148.53 | ₹5,903 Cr | 5.61 | 0.00% | 8.83% | 15.30% | ₹1,053 Cr | ₹85 Cr | |
| ₹333.05 | 48.41 | ₹1,717 Cr | 7.08 | 0.15% | 14.20% | 17.30% | ₹325 Cr | ₹35 Cr | |
| ₹483.05 | 15.84 | ₹1,571 Cr | 1.51 | 0.41% | 10.90% | 12.70% | ₹726 Cr | ₹98 Cr | |
| Median 7 companies | ₹581.25 | 59.74 | ₹7,723 Cr | 8.03 | 0.26% | 14.20% | 17.80% | ₹876 Cr | ₹176 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 73
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 17
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 59
- Good
- Sales & profit trajectory 9% weight
- Financial Health
- 42
- Weak
- Solvency, leverage, coverage 9% weight
- Momentum
- 49
- Average
- Trend strength, vol-adjusted 12% weight
- Ownership
- 43
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
1- Stock is trading at 15.6 times its book value
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 5 | 7 | 7 |
| Oscillators | Bullish | 0 | 7 | 2 |
| Moving Averages | Neutral | 5 | 0 | 5 |
Oscillators
Bullish
Overall
Bullish
Moving Averages
Neutral
Key readings
- RSI (14)
- 47.66
- Neutral
- MACD (12,26,9)
- −3.95
- Bullish
- SMA (50)
- 1,462.08
- Bearish
- SMA (200)
- 1,239.44
- Bullish
As of
Analyst Rating
7 of 8 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 5Y | +16.64% |
|---|---|
| 3Y | +21.04% |
| 1Y | +19.53% |
| TTM | +20.20% |
Net profit
| 5Y | +15.27% |
|---|---|
| 3Y | +26.73% |
| 1Y | +20.14% |
| TTM | +23.84% |
Operating cash flow
| 5Y | +15.83% |
|---|---|
| 3Y | +17.99% |
| 1Y | +20.98% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | −2.63 pp |
|---|---|
| 3Y | +1.75 pp |
| 1Y | +1.31 pp |
| TTM | +2.25 pp |
Revenue by year
| Mar 2018 | ₹251 Cr |
|---|---|
| Mar 2019 | ₹293 Cr |
| Mar 2020 | ₹339 Cr |
| Mar 2021 | ₹377 Cr |
| Mar 2022 | ₹462 Cr |
| Mar 2023 | ₹459 Cr |
| Mar 2024 | ₹548 Cr |
| Mar 2025 | ₹681 Cr |
| Mar 2026 | ₹814 Cr |
Net profit by year
| Mar 2018 | ₹35.00 Cr |
|---|---|
| Mar 2019 | ₹46.00 Cr |
| Mar 2020 | ₹63.00 Cr |
| Mar 2021 | ₹85.00 Cr |
| Mar 2022 | ₹111 Cr |
| Mar 2023 | ₹85.00 Cr |
| Mar 2024 | ₹120 Cr |
| Mar 2025 | ₹144 Cr |
| Mar 2026 | ₹173 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Vijaya Diagnostic Centre Ltd trades at ₹1,442.80 as of 2026-10-28 with a market cap of ₹14,860.51 Cr, a trailing PE of 79.14x, and a price-to-book of 15.53x. The company has delivered compounded sales growth of 21% over three years and profit growth of 24% over the same period, while carrying a modest debt-to-equity ratio of 0.44.
- Strong revenue growth trajectory with TTM compounded sales growth of 20% and a 3-year sales CAGR of 21%, indicating consistent top-line expansion
- Profit growth outpacing revenue growth — TTM compounded profit growth of 24% and 3-year profit CAGR of 24% suggest improving operating leverage and margins
- Healthy return ratios with ROE at 18.07% and ROCE at 19.22% as of 2026-10-28, reflecting efficient capital deployment for a healthcare services company
- Conservative balance sheet with debt-to-equity of just 0.44, providing financial flexibility for expansion without excessive leverage
- Stock has delivered a 1-year return of 48% and a 3-year CAGR of 38%, reflecting strong investor confidence and momentum
- 5-year compounded sales growth of 17% and 5-year ROE averaging 19% demonstrate the business model's durability across cycles
- The diagnostics sector in India benefits from structural tailwinds including rising health awareness, increasing preventive testing, and growing insurance penetration, supporting long-term demand
- Stock is trading at 15.53x book value, well above typical healthcare services peers, implying the market is paying a steep premium for the franchise
- Dividend yield of just 0.14% offers negligible income return, meaning investors are almost entirely dependent on capital appreciation
- At ₹1,442.80 the stock is approximately 9.5% below its 52-week high of ₹1,593.60, suggesting possible near-term resistance at higher levels
- 5-year compounded profit CAGR of 14% is materially lower than the recent 3-year CAGR of 24%, raising the question of whether current profit growth rates are sustainable or benefiting from a favourable base
- The diagnostics industry faces rising competition from national chains, aggregator platforms, and hospital-based labs, which could pressure pricing and market share over time
- With a market cap of ₹14,860.51 Cr, the stock's current valuation already reflects much of the optimistic growth scenario, and any deceleration in quarterly earnings could trigger sharp re-rating downward given the 79.14x PE multiple
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: A quiet period for Vijaya Diagnostic Centre with only a routine corporate governance update — the appointment of a new Company Secretary. No material business developments, financial updates, or risk factors surfaced in recent news. Investors should watch for upcoming quarterly results and expansion plans for directional cues.
- New company secretary appointed Nov 03
Vijaya Diagnostic Centre appointed Rahul Jain as Company Secretary and Compliance Officer effective November 3, 2026. Jain brings over 6 years of experience in corporate secretarial functions and regulatory compliance.
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 139 | 133 | 155 | 156 | 183 | 169 | 173 | 188 | 202 | 205 | 219 | 231 | 255 |
| Expenses | 73 | 82 | 80 | 92 | 95 | 107 | 102 | 104 | 115 | 120 | 119 | 124 | 132 | 143 |
| Operating Profit | 48 | 57 | 52 | 63 | 61 | 76 | 67 | 69 | 74 | 82 | 86 | 96 | 99 | 113 |
| OPM % | 40% | 41% | 39% | 41% | 39% | 42% | 40% | 40% | 39% | 41% | 42% | 44% | 43% | 44% |
| Other Income | 6 | 7 | 5.11 | 3 | 4 | 5 | 5 | 5 | 7 | 6 | 5 | 2 | 9 | — |
| Interest | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 9 | 9 | 11 | 11 |
| Depreciation | 12 | 14 | 15 | 16 | 17 | 17 | 18 | 19 | 21 | 22 | 24 | 24 | 25 | 27 |
| PBT | 35 | 45 | 35 | 44 | 42 | 57 | 47 | 47 | 52 | 58 | 58 | 64 | 71 | 79 |
| Tax % | 26% | 25% | 25% | 23% | 25% | 26% | 24% | 26% | 26% | 25% | 26% | 25% | 25% | 25% |
| Net Profit | 26 | 34 | 26 | 34 | 32 | 42 | 35 | 35 | 39 | 43 | 43 | 48 | 53 | 59 |
| EPS (₹) | 2.57 | 3.26 | 2.53 | 3.27 | 3.06 | 4.1 | 3.43 | 3.4 | 3.76 | 4.21 | 4.2 | 4.66 | 5.16 | — |
Sep 2026: from the results filed on 3 Nov 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 251 | 293 | 339 | 377 | 462 | 459 | 548 | 681 | 814 | 857 |
| Expenses | 171 | 184 | 206 | 211 | 259 | 277 | 327 | 408 | 477 | 495 |
| Operating Profit | 80 | 108 | 133 | 166 | 204 | 182 | 221 | 273 | 337 | 362 |
| OPM % | 32% | 37% | 39% | 44% | 44% | 40% | 40% | 40% | 41% | 42% |
| Other Income | 7 | 10 | 15 | 12 | 13 | 14 | 19 | 17 | 21 | 22 |
| Interest | 5 | 14 | 15 | 15 | 16 | 21 | 24 | 27 | 33 | 37 |
| Depreciation | 26 | 40 | 49 | 50 | 53 | 62 | 57 | 71 | 92 | 96 |
| PBT | 55 | 65 | 83 | 112 | 147 | 114 | 159 | 193 | 233 | 251 |
| Tax % | 37% | 29% | 25% | 24% | 25% | 25% | 25% | 26% | 26% | — |
| Net Profit | 35 | 46 | 63 | 85 | 111 | 85 | 120 | 144 | 173 | 187 |
| EPS (₹) | 77.44 | 101 | 138 | 18.64 | 10.76 | 8.29 | 11.61 | 14.01 | 16.81 | 18.23 |
| Div. Payout % | 0% | 0% | 0% | 0% | 9% | 12% | 9% | 14% | 12% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 157 | 203 | 270 | 354 | 458 | 535 | 647 | 789 | 947 |
| Borrowings | 33 | 146 | 161 | 141 | 183 | 248 | 259 | 320 | 423 |
| Other Liabilities | 39 | 53 | 46 | 41 | 62 | 61 | 66 | 155 | 127 |
| Total Liabilities | 234 | 406 | 482 | 541 | 713 | 853 | 983 | 1,274 | 1,507 |
| Fixed Assets | 119 | 259 | 272 | 268 | 370 | 524 | 742 | 865 | 1,069 |
| CWIP | 3 | 3 | 10 | 9 | 34 | 28 | 9 | 70 | 35 |
| Investments | 73 | 69 | 55 | 28 | 54 | 139 | 109 | 185 | 228 |
| Other Assets | 39 | 76 | 146 | 236 | 255 | 163 | 123 | 154 | 174 |
| Total Assets | 234 | 406 | 482 | 541 | 713 | 853 | 983 | 1,274 | 1,507 |
Cash Flow
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 62 | 91 | 106 | 130 | 158 | 165 | 183 | 224 | 271 |
| Investing | −98 | −90 | −31 | −130 | −123 | −110 | −141 | −182 | −174 |
| Financing | −8 | −7 | −30 | −49 | −31 | −42 | −45 | −52 | −69 |
| Net Cash Flow | −44 | −6 | 46 | −49 | 4 | 13 | −2 | −9 | 27 |
| Free Cash Flow | 32 | 31 | 69 | 98 | 37 | 40 | 99 | 132 | 91 |
| CFO/OP | 103 | 101 | 98 | 97 | 97 | 105 | 98 | 97 | 96 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 12 | 11 | 9 | 6 | 8 | 8 | 11 | 8 | 9 |
| Inventory Days | 24 | 20 | 23 | 17 | 22 | 13 | 29 | 21 | 19 |
| Days Payable | 176 | 196 | 180 | 142 | 110 | 172 | 184 | 143 | 145 |
| Cash Conversion Cycle | −140 | −165 | −149 | −118 | −81 | −152 | −144 | −114 | −117 |
| Working Capital Days | −41 | −51 | −49 | −26 | −34 | −36 | −29 | −48 | −37 |
| ROCE % | — | 28% | 23% | 27% | 28% | 18% | 20% | 21% | 21% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vijaya Diagnostic Centre insights
63 extracted metrics across FY18–FY27.
Documents
- Concall · Sep 2026PPT
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025Transcript PPT Recording
- 25 Jun 2026
- 30 Apr 2025
- 8 Oct 2024
- 29 Feb 2024
- 29 Dec 2023
- General announcements 3 Nov 2026
- Intimation 28 Oct 2026
Frequently Asked Questions about Vijaya Diagnostic Centre
What does Vijaya Diagnostic Centre Ltd do?
Where is Vijaya Diagnostic Centre Ltd (VIJAYA) listed?
Which sector does Vijaya Diagnostic Centre Ltd belong to?
What is the PE ratio of Vijaya Diagnostic Centre Ltd?
What is the 52-week high and low of Vijaya Diagnostic Centre Ltd?
Does Vijaya Diagnostic Centre Ltd pay dividends?
What is the Return on Equity (ROE) of Vijaya Diagnostic Centre Ltd?
Company Information
Vijaya Diagnostics Centre limited is a leading diagnostic medicare services provider in Southern India and offers comprehensive services that include nuclear medicine, radiology, laboratory, health check-ups and medical services. The company provides its services across 13 cities through its 81 diagnostic centers and 11 reference laboratories.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VIJAYA.md for Vijaya Diagnostic Centre Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.